- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00694187
Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions
January 19, 2018 updated by: Roxane Laboratories
A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions.
The objective of this study was to show the bioequivalence of a Roxane Laboratories' Zaleplon Capsules, 10 mg, to Sonata ® Capsules, 10 mg (Jones Pharma) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77042
- Novum Pharmaceutical Research Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Zaleplon or any comparable or similar product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence
Time Frame: Baseline, Two Period, Seven day washout
|
Baseline, Two Period, Seven day washout
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Primary Completion (ACTUAL)
February 1, 2004
Study Completion (ACTUAL)
February 1, 2004
Study Registration Dates
First Submitted
June 6, 2008
First Submitted That Met QC Criteria
June 9, 2008
First Posted (ESTIMATE)
June 10, 2008
Study Record Updates
Last Update Posted (ACTUAL)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 19, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZALE-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Short Term Treatment of Insomnia
-
Roxane LaboratoriesCompletedShort Term Treatment of InsomniaUnited States
-
Prof. Dominique de Quervain, MDClinical Trial Unit, University Hospital Basel, SwitzerlandCompletedMemory, Short-Term | Memory, Long-TermSwitzerland
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingMemory, Short-TermUnited States
-
Korean Medicine Hospital of Pusan National UniversityUnknownMemory, Short-TermKorea, Republic of
-
Beijing Hospital of Traditional Chinese MedicineNot yet recruiting
-
Sequential Medicine LtdClinilabs, Inc.CompletedShort-term Insomnia
-
Universidad de ValparaisoCompletedExecutive Function | Attention | Memory, Short-TermChile
-
Alaa Gameil Abd El-salam HussienAssiut UniversityActive, not recruitingThe Aim of This Study is to Follow up Short Term "3-6 Months"& Mid Term" 6-12months "Outcomes of Vascular Access" Native and Synthetic "in ESRD PediatricsEgypt
-
Beth Israel Deaconess Medical CenterAmgenCompletedEnergy Deficiency Due to Short-term FastingUnited States
-
Beijing Friendship HospitalRecruitingClarify the Difference of Short-term Infection Rate Between Diffrent CatheterChina
Clinical Trials on Zaleplon
-
Alexza Pharmaceuticals, Inc.Completed
-
Somnus Therapeutics, Inc.INC Research LimitedCompletedSleep Disorder | Primary Insomnia
-
Intec Pharma Ltd.Completed
-
Teva Pharmaceuticals USACompleted
-
Teva Pharmaceuticals USACompleted
-
St. Luke's Hospital, Chesterfield, MissouriAmerican Academy of Sleep MedicineCompletedSleep | MemoryUnited States
-
Roxane LaboratoriesCompletedShort Term Treatment of InsomniaUnited States
-
University of RochesterRecruiting
-
University of PennsylvaniaCompleted
-
GynesonicsRecruitingUterine FibroidGermany, Switzerland, United Kingdom